Greece and an international study show that Pfizer-BioNTech’s anti-Covid vaccine is significantly less effective for cancer patients with chronic lymphocytic leukemia (CLL) and multiple myeloma than the general population. According to experts, this is due to blood diseases and also due to the cancer treatment the patient received. The efficacy of the third dose of vaccine was evaluated.
This Coronavirus disease vaccine of Pfizer There are two forms Blood cancer, This Chronic lymphocytic leukemia (CLL)-the most common form of leukemia, especially in men-multiple myeloma is a disease that mainly affects the elderly.What vaccine to use Coronavirus SARS-CoV-2 May be in cancer patient Considering the immune system and the state of the immune system, this is not surprising. horrifying They often experience it, but now they have the results of two scientific studies, which are proved by data.The first study conducted by an international team focused on Chronic lymphocytic leukemia; The second one is led by a Greek researcher, right Multiple myeloma; Both surveys have concluded Reduced effectiveness Vaccine BNT162b2 / Tozinameran Among those who suffer from these diseases.
The research on chronic lymphocytic leukemia was carried out by scientists from Tel Aviv University who worked closely with colleagues from Tel Aviv Sourasky Medical Center, IRCCS San Rafael Institute of Science, Milan Vita Salute San Rafael University, and Milan Memorial Sloan University. Caitlin Cancer Center, New York. Israeli scientists, under the coordination of Professor Yair Herishanu, Professor of Hematology at the University of Israel’s Sackler School of Medicine, came to their conclusions. immune response The vaccination observed in 167 blood cancer patients was compared with the vaccination of 53 healthy subjects (control group). All received two doses BNT162b2 / Tozinameran Pfizer BioNTech research was conducted between December 2020 and February 2021. Press release, The average age is 71 years old, and 67% of them are men. In 58 (34.7%), childishIn other words, they have not received any treatment for leukemia; 75 (44.9%) are following 1 treatment Actively among 24 (14.4%) people totally relaxed Or partly from the disease, of which 10 (6%) relapse.
Analyze the patient’s immune response only in the following cases 4 of your 10 Patients with CLL (39.5%) showed vaccine-triggered antibody activity, compared to 100% in the control group.Observe the best outcome for cancer patients in moles young people, In female, People who still need cancer treatment and people who have already passed cancer treatment. “In general, the response rate of the vaccine is significantly lower than that of the general population. This is probably due to the cancer itself and the existence of certain CLL therapies.” He has announced Professor Herishanu.Although such patients have a reduced risk of reaction, the scientists emphasized that in view of the serious risks, it is strongly recommended to vaccinate the Covid vaccine complication To prevent infection.Research authors speculate Third dose The vaccine may cause a better response, but a special investigation is needed. The details of the study”Efficacy of BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia“Published in the scientific journal “Blood”.
The second multiple myeloma study was carried out by scientists from the National and Koper University of Athens in collaboration with colleagues from the Ghia Sophia Children’s Hospital. The researchers, with the assistance of Evangelos Terpos, a professor at the University of Greece School of Medicine, compared the vaccination results of 48 blood cancer patients and 104 control patients and came to their conclusions. First dose Production of Pfizer’s BioNTech drug.About 3 weeks after my first dose Antibody titer Among all patients (average age 83 years), Neutralizing antibody in 20.6% People with multiple myeloma 32.5% Than healthier. Similarly, patients receiving anti-myeloma treatment have the worst immune response. Greek scientists emphasized the importance of timely management of liver cancer. Second dose Anti-Covid vaccines are used in blood cancer patients to ensure that “immune shields” are generated as soon as possible. the study”Low neutralizing antibody response of elderly myeloma patients to SARS-CoV-2 after the first vaccination of BNT162b2 vaccinePublished in the professional scientific journal “Blood”.